Evidence map›Paper›PMID 18982351›Full record

ReviewEuropean journal of pediatrics2009

Vitamin K, an update for the paediatrician.

Myriam Van Winckel, Ruth De Bruyne, Saskia Van De Velde, Stephanie Van Biervliet

Abstract readReview
PubMed Publisher
In one paragraph

Review in European journal of pediatrics, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 2 pooled it
7.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 2 syntheses or guidelines pooled it, 130 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Observational
  5. Vitamin K Deficiency: Diagnosis and Management.Annals of laboratory medicine · 2025
    Review
  6. Bioactive Compounds of Sea Mustard (Foods (Basel, Switzerland) · 2024
    Article
  7. Vitamin K prophylaxis in neonates: comparing two different oral regimens.Journal of perinatology : official journal of the California Perinatal Association · 2024
    Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Main nutritional deficiencies.Journal of preventive medicine and hygiene · 2022
    Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Myriam Van WinckelDepartment of Paediatrics, UZ Gent, De Pintelaan 185, 9000 Ghent, Belgium. myriam.vanwinckel@ugent.be
Ruth De Bruyne
Saskia Van De Velde
Stephanie Van Biervliet
Ghent University · BEGhent University Hospital · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThis review summarizes current knowledge on vitamin K for the paediatrician. Vitamin K is a fat-soluble vitamin, present in plants as phylloquinone and produced by bacteria as menaquinone. It is acting as a co-factor for gamma-glutamyl carboxylase. This enzyme is responsible for post-translational modification of some glutamate side chains to gamma-carboxyglutamate. The majority of gamma-carboxylated proteins function in blood coagulation; others play a role in calcium homeostasis. DATA: Newborn babies are at particular risk of vitamin K deficiency, as placental transfer is limited and human milk is a poor source. Vitamin K prophylaxis at birth effectively prevents vitamin K deficiency bleeding (VKDB), formerly known as "haemorrhagic disease of the newborn". Recent epidemiological studies provide data on the effectiveness of different administration routes and dosing schemes. Infants of mothers taking drugs that inhibit vitamin K are at risk of early VKDB and should receive 1 mg intramuscular (i.m.) as soon as possible after birth. Classic VKDB is prevented by intramuscular as well as by oral administration of 1 mg vitamin K. In exclusively breast-fed infants, single i.m. administration at birth is also effectively preventing (rare) late VKDB but single oral administration is not. If given orally, prophylaxis should be continued by either weekly administration of 1 mg till 12 weeks or repeating 2 mg at weeks 1 and 4. Daily administration of 25 microg offers insufficient protection. The only infants not fully protected in this way are those with yet unrecognised liver disease.

conclusionsFurther work is needed before firm recommendations can be made regarding dose in preterm infants and in patients with fat malabsorption/cholestasis or regarding the role of vitamin K in the prevention of osteoporosis.

Indexed as

Administration, OralBlood CoagulationBreast FeedingCalciumDose-Response Relationship, DrugDrug Administration ScheduleHomeostasisHumansInfant, NewbornInfant, Premature, DiseasesInjections, IntramuscularLiverRisk FactorsVitamin KVitamin K 1Vitamin K 2CalciumVitamin KVitamin K 1Vitamin K 2

Identifiers

PMID18982351
OpenAlexW2064863324

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.